European Commission Authorizes RINVOQ for Severe Alopecia Areata

The European Commission has officially granted marketing authorization for AbbVie’s RINVOQ (upadacitinib) for the treatment of severe alopecia areata in patients 12 years of age and older.

This approval encompasses both the 15 mg and 30 mg once-daily oral dosing regimens, marking a significant expansion for the JAK inhibitor in the autoimmune therapeutic space. The drug is indicated for individuals experiencing significant hair loss, a condition frequently associated with profound psychological impacts, including a 40% higher incidence of depression and anxiety compared to the general population.

Key Regulatory Proposals

The authorization is anchored in the robust data generated by the Phase 3 UP-AA clinical program, which evaluated 1,399 participants between the ages of 12 and 64 across 248 international sites. The program utilized a dual-period study design: Period A involved a 24-week randomized, double-blind, placebo-controlled trial, while Period B facilitated a 28-week extension. Eligible participants may further enroll in a long-term follow-up study extending to 108 weeks.

Data from the primary 24-week assessment showed that both the 15 mg and 30 mg doses met the primary endpoint of achieving a Severity of Alopecia Tool (SALT) score of 20 or less.

Notably, RINVOQ achieved statistical significance in reaching a SALT score of 0, representing complete scalp hair regrowth, making it the first JAK inhibitor to demonstrate such results against a placebo at the 24-week mark.

Additional secondary endpoints, including improvements in eyebrow and eyelash regrowth, were also satisfied, with the safety profile remaining consistent with existing regulatory approvals for the drug.

This regulatory milestone reinforces a broader transition within the pharmaceutical industry: the reclassification of alopecia areata from a cosmetic concern to a recognized, serious immunological disease. As clinical evidence regarding the physical and mental health burden of the condition strengthens, healthcare payers face increasing pressure to formalize and streamline coverage policies.

Furthermore, the entry of upadacitinib into this treatment category is expected to intensify competition among manufacturers, as firms increasingly prioritize high-growth autoimmune markets for their research and development investment.